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Therapeutic interference with virus-cell surface receptor interactions represents a viable antiviral strategy.
Here we demonstrate that cytoplasmic expression of the serine protease inhibitor (serpin), plasminogen
activator inhibitor type 2 (PAI-2), affords a high level of protection from lytic infection by multiple human
picornaviruses. The antiviral action of PAI-2 was mediated primarily through transcriptional down-regulation
of the following virus receptors: intercellular adhesion molecule 1 (ICAM-1, a cellular receptor for the major
group of rhinoviruses), decay-accelerating factor (a cellular receptor for echoviruses and coxsackieviruses),
and to a lesser extent the coxsackie-adenovirus receptor protein (a cellular receptor for group B coxsackievi-
ruses and group C adenoviruses). Expression of related cell surface receptors, including membrane cofactor
protein and the poliovirus receptor, remained unaffected. These findings suggest that PAI-2 and/or related
serpins may form the basis of novel antiviral strategies against picornavirus infections and also therapeutic
interventions against ICAM-1-mediated respiratory inflammation.
Picornaviruses are small, spherical, naked viruses (20 to 25
nm) containing positive-sense genomic RNA and comprise a
genus of the family Picornaviridae. The two largest subgroups
are rhinoviruses and enteroviruses. There are ;100 rhinovirus
serotypes, which collectively constitute the most important
cause of mild upper respiratory illnesses in adults. The human
enteroviruses consist of polioviruses (3 serotypes), echoviruses
(34 serotypes), group A coxsackieviruses (24 serotypes), and
group B coxsackieviruses (6 serotypes). The human enterovi-
ruses are ubiquitous; transmitted primarily by the oral-fecal
route, they are capable of producing a wide range of clinical
syndromes varying in severity. They are mainly found in the
gastrointestinal tracts of infected individuals but also have the
potential to infect the meninges, central nervous system, myo-
cardium, pericardium, striated muscles, respiratory tract, and
skin (23).
Identification and molecular characterization of virus-spe-
cific receptors and receptor-mediated processes are important
not only because receptors determine host range, susceptibility
to infection, and pathogenesis but also because virus receptors
constitute potential targets for antiviral therapy. Three major
groups of cell surface molecules have been shown to be in-
volved with distinct stages of picornaviral cell attachment and
membrane penetration: the immunoglobulin-like supergene
family, complement regulatory proteins, and integrins. The
poliovirus receptor (PVR) (24), intercellular adhesion mole-
cule 1 (ICAM-1) (16), and coxsackievirus-adenovirus receptor
(CAR) (8, 36) are all members of the immunoglobulin-like
supergene family (Fig. 1) and are able to facilitate productive
cell infection by polioviruses (24), a major group of rhinovi-
ruses (16), and some group A (31) and group B (8, 33, 36)
coxsackieviruses, respectively. In contrast, the complement
regulatory protein, decay-accelerating factor (DAF) (28) (Fig.
1), is employed as an attachment or sequestering receptor by
many enteroviruses (6, 7, 17, 30, 32, 41) but cannot by itself
mediate entry of virus into the cell (7, 30) unless cross-linked
by specific antibody (34, 34a). Additionally, a number of inte-
grins have been shown to bind human picornaviruses, but their
role in viral cell entry is uncertain (1, 5, 29). Recently, a
number of picornaviruses have been shown to employ com-
plexes of the above-mentioned receptors to enter cells, these
receptor complexes consisting of distinct attachment and cell
internalizing components (32, 33).
The cellular expression of many picornavirus receptors is
strongly influenced by the action of inflammatory cytokines
(10, 26, 35, 37). Human rhinoviruses (HRVs) enhance their
own dissemination by up-regulating the cell surface expression
of ICAM-1 on neighboring cells through cytokine induction.
ICAM-1 is highly susceptible to up-regulation via the inflam-
matory cytokines tumor necrosis factor alpha (TNF-a) and
interleukin-1b (IL-1b) (37), and during initial stages of cellular
lytic infection by HRVs, cytokines such as TNF-a and IL-1b
are released by infected cells (35). Furthermore, the expression
of CAR on the surface of colon carcinoma cells is markedly
increased by the action of TNF-a (1a).
The expression of DAF, a major picornavirus attachment
receptor, has been shown to be significantly up-regulated by
the action of TNF-a (10, 26). In contrast, another member of
the complement regulatory protein family, membrane cofactor
protein (MCP; CD46), which is also a cellular receptor for
measles viruses, is resistant to TNF-a-induced up-regulation
(10, 26, 38). Thus, the ability to negate TNF-a-induced up-
regulation of cellular virus receptors might be regarded a po-
tential antiviral strategy for controlling human picornavirus
infections.
TNF-a, in addition to up-regulating numerous cellular pro-
teins, is also able to promote apoptosis in many cells (40).
Recently, cells expressing plasminogen activator inhibitor type
2 (PAI-2) were shown to be protected from TNF-a-induced
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apoptosis (13, 21). PAI-2 is a serine proteinase inhibitor (ser-
pin), which is a major product of macrophages in response to
endotoxin and inflammatory cytokines (20). Under physiolog-
ical conditions, PAI-2 expression is limited to a select number
of cell types, which include differentiated keratinocytes, acti-
vated monocytes and macrophages, placental trophoblasts, and
some tumor cell lines (20). PAI-2 is well characterized as an
inhibitor of the extracellular proteinase urokinase-type plas-
minogen activator (20, 39). Recently, an additional, distinct,
intracellular function for PAI-2 as a regulator of the intracel-
lular signal transduction pathway(s) has been postulated (3,
13). Intracellular PAI-2 expression in HeLa cells was associ-
ated with resistance to TNF-a-mediated apoptosis (13) and
with increased alpha/beta interferon (IFN-a/b) activity (3).
PAI-2 is a member of the ovalbumin group of serpins (ov-
serpins), which lack hydrophobic signal sequences. This results
in inefficient secretion and translocation and thus a primarily
cytoplasmic location of these proteins. In the case of HeLa
cells expressing PAI-2, no secreted PAI-2 is detectable. Apart
from PAI-2, a number of other ov-serpins have now been
shown to have cytoplasmic functions; these include CrmA (15),
protease inhibitor 9 (9), and protease inhibitor 6 (27).
Here we show that expression of PAI-2 in HeLa cells signif-
icantly reduced picornavirus infection through transcriptional
down-regulation of the expression of TNF-a-inducible virus
receptors. These findings may find application in the develop-
ment of a novel serpin-based antiviral strategies for control of
enteric picornavirus infections, and also for the therapeutic
reduction of ICAM-1-mediated respiratory inflammations.
MATERIALS AND METHODS
Cells and viruses. Echovirus type 7 (EH7; Wallace), poliovirus type 1 (PV1;
Sabin), coxsackievirus A21 (CVA21; KuyKendall), coxsackievirus B3 (CVB3;
Nancy), and HeLa B cells were obtained from Margery Kennett, Enterorespi-
ratory Laboratory, Fairfield Hospital, Melbourne, Victoria, Australia. HRV type
14 (HRV14) was obtained from the American Type Culture Collection. All
viruses were grown in HeLa B cells.
A panel of individual cloned HeLa cell lines expressing sense (S1a and S1b)
and antisense (A2/7) PAI-2 cDNA was generated as previously described (13) by
inserting a DNA fragment containing the entire PAI-2 coding sequence and the
39 untranslated region in both orientations into the expression vector pRcCMV
under control of the constitutive cytomegalovirus V promoter. Stable transfec-
tants containing these constructs were selected by resistance to G418 and char-
acterized by Northern blot, immunoblot, and immunofluorescence analyses (13,
14). HeLa and A2/7 cells express no detectable PAI-2 mRNA or protein. S1a and
S1b cell lines each express cytoplasmic PAI-2 at levels similar to or less than
those detected in activated monocytic cells (13).
Antibodies. The anti-ICAM-1 monoclonal antibody (MAb) WEHI (11) was
obtained from Andrew Boyd, Queensland Institute of Medical Research, Bris-
bane, Australia. The anti-DAF MAbs IA10, VIIIA7, and IIH6 (18) were gener-
ous gifts from Taroh Kinoshita, Department of Immunoregulation, Osaka Uni-
versity, Osaka, Japan; MAb IH4 and anti-MCP MAb E4.3 (12) were from Bruce
Loveland, Austin Research Institute, Heidelberg, Victoria, Australia. The anti-
PVR MAb 280 (25) was supplied by Philip Minor, National Institute for Bio-
logical Standards and Control, Potters Bar, United Kingdom, and the anti-CAR
MAb (8) was from Jeffery Bergelson, Dana-Farber Cancer Institute, Boston,
Mass.
Virus infectivity assay. Cell monolayers in 96-well culture plates were chal-
lenged with 100 ml of 10-fold serial dilutions of the above-mentioned picornavi-
ruses and then incubated at 37°C for 48 h. To quantitate cell survival, monolayers
were stained with a crystal violet-methanol solution and washed with distilled
water, and the plates were read at a wavelength of 540 nm. Results are expressed
as mean percentages of cell lysis relative to the uninfected control cell mono-
layers of triplicate wells 1 standard deviation.
Radiolabeled virus binding assays. Viruses were radiolabeled in Dulbecco’s
modified essential medium containing [35S]methionine and purified by velocity
centrifugation in 5 to 30% sucrose gradients as previously described (32). Mono-
layers of PAI-2-expressing S1a and S1b cells and parental HeLa cells were
incubated with radiolabeled viruses (2 3 104 to 5 3 104 cpm) in serum-free
Dulbecco’s modified essential medium for 1 h at 37°C. After three washes, the
cell monolayers were dissolved in 200 ml of 0.2 M NaOH–1.0% sodium dodecyl
sulfate (SDS). The amount of labeled virus bound was measured by liquid
scintillation counting.
Flow cytometry. Cells (5 3 105) were incubated with the appropriate MAbs
(5.0 mg/ml) diluted in phosphate-buffered saline (PBS) containing 1% bovine
serum albumin (PBS-BSA) at 0°C for 30 min, after which the cells were washed
with 5.0 ml of PBS-BSA. The cells were then pelleted at 1,000 3 g for 5 min and
resuspended in 100 ml of phycoerythrin-conjugated goat anti-mouse immuno-
globulin G (heavy plus light chains) (Silenus, Melbourne, Victoria, Australia)
diluted in PBS-BSA. After incubation at 0°C for 30 min, the cells were washed
and pelleted as described above, resuspended in PBS-BSA, and analyzed with a
FACStar analyzer (Becton Dickinson, Sydney, New South Wales, Australia).
Surface biotinylation and immunoprecipitation. Cells (5 3 106) were de-
tached from the surface of plastic tissue culture flasks by using an EDTA solution
and washed once in PBS. Washed cells were resuspended into 3 ml of biotiny-
lation buffer (10 nM sodium borate [pH 8.8], 150 nM NaCl). Biotin-amidocap-
roate N-hydroxysuccinimide ester was added to 50 mg/ml, and the sample stood
at room temperature for 15 min. The reaction was terminated by the addition of
NH4Cl to 10 mM. Cells were washed twice in PBS and resuspended into buffer
A (138 mM NaCl, 2.9 mM KCl, 0.5 mM MgCl2, 12 mM NaHCO3, 0.3 mM
NaH2PO4, 5.5 mM glucose, 10 mM HEPES [pH 7.4]). Cell lysates were placed
on ice for 60 min and then centrifuged at 15,000 3 g for 15 min to remove
detergent-insoluble material. Soluble lysates were precleared with rabbit anti-
mouse immunoglobulin G coupled to Sepharose 4B. Immunocomplexes were
washed three times with lysis buffer and resolved (reduced) by SDS-polyacryl-
amide gel electrophoresis. Resolved proteins were electrophoretically trans-
ferred to nitrocellulose membranes. Streptavidin-biotin-horseradish peroxidase
complexes were used to probe the membrane, and labeled proteins were visu-
alized by using enhanced chemiluminescence (Amersham Life Sciences, Little
Chalfont, United Kingdom).
Northern blot analysis. Total RNA isolated from S1a, S1b, A2/7, and parental
HeLa cells was separated by denaturing gel electrophoresis and transferred to
Hybond-N nylon membranes as described elsewhere (2). The blot was hybridized
with [32P]dCTP-labeled purified DNA fragments encoding cDNAs for ICAM-1
(30), DAF (30), CAR (8), and PVR (24). Blots were hybridized at 65°C and
washed to a final stringency of 0.13 SSC (13 SSC is 0.15 M NaCl plus 0.015 M
sodium citrate)–0.1% SDS at 65°C. The level of 18S rRNA was used as a
measure of RNA loading in each lane.
RESULTS
PAI-2 expression inhibits HeLa cell lytic infection by many
picornaviruses. Monolayers of S1a, S1b, A2/7, and parental
HeLa cells were challenged (105 PFU/well) with PV1, HRV14,
E7, CAV21, and CVB3 and examined for cytopathic effect
following a 48-h incubation period. The cell lines not express-
ing PAI-2 (HeLa and A2/7) were susceptible to lytic infection
by all of these picornaviruses (Fig. 2). In contrast, PAI-2-
expressing S1a cells were refractory to lytic infection by
HRV14, E7, CAV21, and CVB3 but not PV1 (Fig. 2).
To determine whether infection of PAI-2-expressing cells
was noncytopathic but still productive, monolayers of HeLa
FIG. 1. Schematic representation of structures of the virus receptors
ICAM-1, PVR, CAR, MCP, and DAF. ICAM-1, PVR, and CAR belong to the
immunoglobulin supergene family, and MCP and DAF are complement regula-
tory proteins. ICAM-1 is an internalization receptor for rhinoviruses and some
group A coxsackieviruses. CAR is an internalization receptor for group B cox-
sackieviruses. DAF is a sequestration receptor for coxsackieviruses, echoviruses,
and enteroviruses. C2, constant region 2; V, variable region; SCR, short consen-
sus repeat.
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and S1a cells in six-well plates were infected with inocula of 105
and 103 PFU of CVB3. Following incubation for 24 h, cell lysis
was evident only in the inoculated HeLa cells. Analysis of
infectious virus production by plaque assay revealed that
S1a cells yielded titers attributable to that of the input virus,
whereas HeLa cell lysates yielded increases of 103- and
105-fold, respectively, over the input inoculum (data not
shown).
To further quantitate the antiviral effect of PAI-2 expres-
sion, monolayers of HeLa, A2/7, and S1a cells were infected
with 10-fold serial dilutions of PV1, HRV14, E7, CAV21, and
CVB3. HeLa and A2/7 cells showed higher levels of cell lysis
than S1a cells for all dilutions of HRV14, E7, CAV21, and
CVB3 (Fig. 3). S1b cells behaved similarly to S1a cells in these
assays (data not shown). At low dilutions (or high multiplicity
of infection [MOI]) of PV1, no difference between cytopathic
effect of S1a cells and control cells was observed; however, at
high dilutions of virus (low MOI), S1a cells showed increased
survival (low percent lysis) relative to control lines (Fig. 3).
The lower cell lysis values for E7 and HRV infection of
control cell lines at high virus dilutions than for CAV21 and
CVB3 infection reflect a lower replication competence of E7
FIG. 2. Picornavirus-induced lytic infection of PAI-2-expressing S1a cells and control A2/7 and parental HeLa cells. Monolayers of S1a, A2/7, and HeLa cells in
96-well culture plates were inoculated (approximately 105 PFU/well) with PV1, HRV14, E7, CAV21, and CVB3. Following incubation for 48 h at 37°C, the cell
monolayers were inspected for signs of cell lysis and then photographed at an original magnification of 320.
FIG. 3. Dose-dependent picornavirus-induced lytic infection of S1a, A2/7, and HeLa cells, using a range of input multiplicities of PV1, HRV14, E7, CAV21, and
CVB3.
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and HRV in HeLa cells and thus less lysis within the 48-h assay
period.
Thus, HeLa and A2/7 cells were substantially more suscep-
tible than PAI-2-expressing cells to the cytopathic effects of
HRV14, E7, CAV21, and CVB3 infection. Picornaviral rep-
lication appeared not to be modified by PAI-2 cytoplasmic
expression, as HeLa and PAI-2-expressing S1a cells yielded
comparable levels of infectious CAV21 and CVB3 when
transfected with CAV21 and CVB3 viral RNAs, respectively
(data not shown).
Reduced binding of picornaviruses to PAI-2-expressing
cells. To determine whether inhibition of picornavirus lytic
infection in S1a and S1b cells was due to interference with
cellular attachment, preparations of gradient-purified picorna-
viruses were radiolabeled (Fig. 4A) and incubated with S1a,
S1b, and HeLa cells to monitor relative levels of virus-cell
surface binding. Cellular attachment of E7, HRV14, CAV21,
and CVB3 was reduced by between 80 and 95% in S1a and S1b
cells compared to HeLa controls (Fig. 4B). PV1 bound equally
to S1a, S1b, and HeLa cell lines, albeit with a slight increase in
binding to S1b cells compared with HeLa cells (Fig. 4B).
The overall pattern of reduced virus binding to the panel of
cells was similar to the pattern observed for inhibition of virus-
induced lytic infection shown in Fig. 2 and 3, suggesting that
the presence of PAI-2 reduced the surface expression of pi-
cornavirus cellular receptors.
PAI-2 reduces surface expression of picornavirus receptors.
To determine whether PAI-2-transfected cells expressed lower
levels of virus receptors, which would result in less virus bind-
ing (Fig. 4) and less cell infection (Fig. 2 and 3), the levels of
the picornavirus receptor molecules PVR, CAR, DAF, and
ICAM-1 were assessed by flow cytometry. The cellular recep-
tor of the unrelated measles virus, MCP, was included as a
control. Measurement of the mean peak fluorescence intensi-
ties showed that expression of CAR, DAF, and ICAM-1 on the
surface of S1a and S1b cells compared to A2/7 cells was re-
duced by 50 to 90% (Fig. 5A). The surface expression of PVR
and MCP was similar among all cell lines, indicating that these
receptors were unaffected by PAI-2 expression. (Results for
the parent HeLa cell line were similar to those for A2/7 cells in
these assays [data not shown]). The slight increase in PV1
binding to S1b cells observed in Fig. 4B was mirrored by a
slight increase in the level of PVR on S1b cells (Fig. 5A). The
decreased picornavirus receptor expression on the surface of
PAI-2-expressing HeLa cells was not due to an accident of the
transfection and selection process, as the antisense PAI-2
clone A2/7 (Fig. 5) and a chloramphenicol acetyltransferase-
expressing HeLa clone generated by the same protocol as used
for the S1a and S1b cells showed no signs of reduced surface
ICAM-1 expression (35a).
To confirm that PAI-2 selectively reduced surface expression
of CAR, DAF, and ICAM-1, S1a cells and A2/7 cells were
surface biotinylated and immunoprecipitated with anti-DAF,
anti-CAR, and anti-ICAM-1 MAbs. The level of surface ex-
pression of biotinylated DAF and CAR was significantly less
on the surface of S1a cells than on the surface of A2/7 cells.
ICAM-1 expression differed dramatically between the two cell
lines, being undetectable on the surface of S1a cells (Fig. 5B).
The reduction in CAR, DAF, and ICAM-1 expression on the
surface of PAI-2-expressing S1a cells (Fig. 5B) mirrored that
detected by flow cytometry (Fig. 5A).
These data clearly show a reduction in the expression of the
picornavirus receptors CAR, DAF, and ICAM-1 in PAI-2 ex-
pressing cells, while PVR and MCP were unaffected.
PAI-2-mediated picornavirus receptor down-regulation oc-
curs at the transcriptional level. To ascertain whether PAI-2-
induced picornavirus receptor down-regulation was mediated
by transcriptional or posttranscriptional activity, mRNA levels
for ICAM-1, DAF, and PVR were examined in PAI-2-express-
ing and control cell lines. Significant levels of PVR mRNA
were detected in each cell line (S1a, S1b, A2/7, and HeLa)
independent of expression of PAI-2 (Fig. 6). ICAM-1 and
DAF mRNAs were present in HeLa and A2/7 cells, but no
ICAM-1 or DAF mRNA was detected in PAI-2-expressing S1a
and S1b cells (Fig. 6). A marked reduction in the CAR mRNA
level was observed in the S1a cells but not in S1b cells (data not
shown). This may be due to the finding that S1a cells express
significantly higher levels of intracellular PAI-2 than S1b cells
FIG. 4. Picornavirus binding to S1a, A2/7, and parental HeLa cells. (A) 35S-labeled preparations of PV1, HRV14, E7, CAV21, and CVB3 were separated on a 15%
slab SDS-polyacrylamide gel, and individual proteins identified by autoradiography. (B) Monolayers of PAI-2-expressing S1a and S1b cells and parental HeLa cells were
incubated with radiolabeled viruses and washed, and the amount of labeled virus bound was measured by liquid scintillation counting. Results are expressed as the mean
of triplicate wells 1 standard deviation.
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(3a), which raises the possibility that the intracellular threshold
PAI-2 level required for CAR down-regulation is higher than
that needed for DAF and ICAM-1 down-regulation. The levels
of the loading control, 18S and 28S rRNAs, were comparable
in all the samples. These findings demonstrated that the re-
duction in the expression of picornavirus receptors in PAI-2-
expressing cells was due to a reduction in their gene transcrip-
tion.
DISCUSSION
This study demonstrated that expression of PAI-2 protected
the highly permissive HeLa cells against lytic infection by se-
lected human picornaviruses (Fig. 2 and 3). The primary mode
of action was a PAI-2-dependent transcriptional down-regula-
tion of the surface expression of three picornavirus cellular
receptors, DAF, CAR, and ICAM-1 (Fig. 6). The surface ex-
pression of other virus receptors, namely, PVR and MCP,
although closely related to CAR/ICAM-1 and DAF (Fig. 1),
respectively, were unaffected by cytoplasmic expression of
PAI-2 (Fig. 5).
Cytoplasmic expression of PAI-2 has been shown to protect
cells against TNF-a-mediated apoptosis (13, 21), and here we
show that PAI-2 expression significantly reduced the surface
expression of the virus receptor molecules DAF, CAR, and
ICAM-1, which are all known to be TNF-a inducible (10, 26,
37). In contrast, PVR and MCP were not inducible by TNF-a,
and their expression was largely unaffected by PAI-2 expres-
sion. The structural relatedness of PVR, CAR, and ICAM-1
and of DAF and MCP (Fig. 1) appeared to have no bearing on
the PAI-2-mediated effects. Thus, PAI-2 appeared to selec-
tively down-regulate TNF-a-inducible receptors, although the
expression of the TNF-a-inducible HLA class I was not af-
fected by PAI-2 expression (data not shown). These experi-
ments suggest that PAI-2 has activity as a specific intracellular
regulator of gene expression, consistent with previous reports
of a PAI-2-mediated influence on the signal transduction path-
way(s) (3, 13, 14).
Antalis et al. (3) recently described another phenotype of
PAI-2-expressing HeLa cells whereby the cells were protected
from the rapid cytopathic effects of alphavirus infection via a
PAI-2-mediated induction of constitutive IFN-a/b production
(3). The replication of many picornaviruses has been shown to
be inhibited by the action of IFN-a/b (19, 22). The antiviral
action of IFN-a/b may provide an explanation for the protec-
tion against poliovirus lytic infection seen in PAI-2-expressing
cells at low MOI (Fig. 3), in the absence of receptor down-
regulation or reduction in viral binding (Fig. 4 and 5). The
antipicornaviral activity of PAI-2 may thus be twofold: (i) the
major component via receptor down-regulation and reduction
of viral binding and (ii) a minor component via inhibition of
viral replication through the action of autocrine IFN-a/b.
Picornavirus infections are a major cause of morbidity in our
community, with symptoms ranging from the common cold to
pericarditis. For many of these viruses, the large number of
serotypes makes vaccine development difficult. In recent years,
much research effort has been directed at characterizing the
cellular receptors used by viruses and the molecular basis of
virus-receptor interactions, with the ultimate aim of developing
generic antiviral strategies. Here we show that a specific serpin
can transcriptionally down-regulate specific viral receptors, il-
lustrating the potential for novel serpin based antiviral strate-
gies for a large proportion of picornavirus infections.
ICAM-1 plays an important role in the pathogenesis of not
only rhinovirus infection but also Plasmodium falciparum in-
fection (4) and the exacerbations of asthma, chronic bronchitis,
and cystic fibrosis (42). ICAM-1 was the most susceptible to
the action of cytoplasmic PAI-2 expression, indicating that
PAI-2-based therapy may also find application in the reduction
of ICAM-1-mediated respiratory inflammations.
FIG. 5. Analysis of picornavirus receptor expression on the surface of S1a,
S1b, and HeLa cells. (A) Flow cytometric analysis of receptor surface expression.
Suspensions of S1a, S1b, A2/7, and HeLa cells were incubated with MAbs against
the virus receptors PVR, ICAM-1, DAF, CAR, and MCP. (B) Immunoprecipi-
tation of biotinylated virus receptors. S1a and A2/7 cells were surface biotinyl-
ated and then immunoprecipitated with anti-DAF, anti-ICAM-1, and anti-CAR
MAbs, as indicated. Sizes are indicated in kilodaltons.
FIG. 6. Northern blot analysis of virus receptor expression in PAI-2-express-
ing S1a and S1b cells and control A2/7 and HeLa cells. Total RNA was isolated
from each cell line, separated by denaturing gel electrophoresis, and Northern
blotted, and the membranes were probed with radiolabeled cDNA fragments
encoding each receptor. Levels of 18S and 28S rRNAs are shown as a measure
of RNA loading in each lane.
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